Table 3. HR value of the overall survival in breast cancer subgroups according to year, N pts, methods of detecting STAT3 expression, biomarker, race.
| Stratification | Pooled HR (95% CI) Random effects | I2(%) | p value of Q test |
|---|---|---|---|
| Year | |||
| ≤ 2010 | 0.85 (0.41–1.78) | 82.3 | 0.000 |
| > 2010 | 0.98 (0.58–1.65) | 63.8 | 0.011 |
| N pts | |||
| ≥ 100 | 0.94 (0.60–1.45) | 76.8 | 0.000 |
| < 100 | 1.08 (0.09–13.22) | 88.0 | 0.004 |
| IHC scoring method | |||
| Multiply score | 0.93 (0.56–1.52) | 59.2 | 0.016 |
| Non-multiply score | 0.92 (0.42–2.02) | 85.6 | 0.000 |
| Biomarker | |||
| STAT3 | 1.87 (1.42–2.45) | 49.1 | 0.117 |
| P-STAT3 | 0.72 (0.57–0.91) | 39.1 | 0.131 |
| Race | |||
| non-Asian | 0.57 (0.37–0.88) | 50.7 | 0.108 |
| Asian | 1.42 (0.88–2.31) | 58.5 | 0.018 |
Table 3. N pts, number of patients; IHC, immunohistochemistry; HR, hazard ratio; 95% CI, 95% confidence interval.